References
- Howden C W, Jones D B, Peace K E, et al. The treatment of gastric ulcer with antisecretory drugs. Relationship of pharmacological effect to healing rates. Dig Dis Sci 1988; 33: 619–24
- Hunt R H, Howden C W, Jones D B, Burget D W, Kerr G D. The correlation between acid suppression and peptic ulcer healing. Scand J Gastroenterol 1986; 21(Suppl 125)22–9
- McTavish D, Buckley M MT, Heel R C. Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs 1991; 42: 138–70
- Barradell L B, Faulds D, McTavish D. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992; 44: 225–50
- Barbara L, et al. (Italian cooperative group on omeprazole). Omeprazole 20 mg uid and ranitidine 150 mg bid in the treatment of benign gastric ulcer. Hepatogastroenterology 1991; 38: 400–3
- Walan A, Bader J P, Classen M, Lamers C BHW, Piper D W, Rutgersson K, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320: 69–75
- Classen M, Dammann H G, Domschke W, et al. Healing rates following omeprazole and ranitidine treatment of gastric ulcer: results of a German multicenter study. Dtsch Med Wochenschr 1985; 110: 628–33
- Simon W A, Keeling D J, Laing S M, et al. BY1023/SK&F96022: biochemistry of a novel (H+K+)-ATPase inhibitor. Biochem Pharmacol 1990; 39: 1799–806
- Hartmann M, Theiß U, Bliesath H, Kuhn I, Lühmann R, Huber R, et al. 24 h intragastric pH following oral intake of pantoprazole and omeprazole. Hellenic J Gastroenterol 1992; 5: 112, Suppl
- Kromer W, Postius S, Riedel R, Simon W A, Hanauer G, Brand U, et al. BY1023/SK&F96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P 450 interactions. J Pharmacol Exp Ther 1990; 254: 129–35
- Simon W A, Büdingen C, Fahr S, Kinder B, Koske M. The H+K+-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole. Biochem Pharmacol 1991; 42: 347–55
- Hanauer G, Graf U, Meissner T. In vivo cytochrome P 450 interactions of the newly developed H + -K + -ATPase inhibitor pantoprazole (BY1023/SK&F 96022) compared to other antiulcer drugs. Meth Find Exp Clin Pharmacol 1991; 13: 63–7
- Gugler R, Hartmann M, Rudi J, Bliesath H, Brod I, Klotz U. Lack of interaction of pantoprazole and diazepam in man. Gastroenterology 1992; 102(4, Pt 2)A77
- De Mey C, Meineke I, Steinijans V W, et al. Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. Int J Clin Pharm Ther 1994; 32: 98–106
- Schulz H U, Hartmann M, Steinijans V W, et al. Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. Int J Clin Pharm Ther Tox 1991; 29: 369–75
- Müller P, Simon B, Khalil H, et al. Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. Z Gastroenterol 1992; 30: 771–5
- Judmaier G, Koelz H R, pantoprazole-duodenal ulcer study group. Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Aliment Pharmacol Ther 1994; 8: 81–6
- Blum A L. Treatment of acid-related disorders with gastric acid inhibitors: the state of the art. Digestion 1990; 47(Suppl 1)3–10
- Maton P N. Omeprazole. N Engl J Med 1991; 324: 965–75
- Darragh Montgomery R, Richardson B P. Gastric ulcer and cancer. Q J Med New Series 1975; XLIV(No. 176)591–9
- Mountford R A, Brown P, Salmon P R, Alvarenga C, Neumann C S, Read A E. Gastric cancer detection in gastric ulcer disease. Gut 1980; 21: 9–17
- Creutzfeld W. Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders. Drug Safety 1994; 10: 66–82
- Humphries T. Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Dig Dis Sci 1991; 36: 1665–9